You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R41/R42- Clinical Trial Optional)

    SBC: Brightline Interactive LLC            Topic: NIDA

    Randamp;R Other Project Information 7. Project Summary/Abstract Neurobiological changes caused by addiction impair behavioral control and increase relapse risk (Volkow, Koob, andamp; McLellan, 2016), substantiating the need for long-term care coordination and recovery engagement for individuals with Substance Use Disorders (SUD) (Humphreys, Malenka, Knutson, andamp; MacCoun, 2017). Because addicti ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    The advent of checkpoint inhibitor (CPI) therapy in human cancer has dramatically changed the landscape of treatment strategies in recent years. Previously, cancers with largely ineffective therapeutics and a poor prognosis, such as melanoma, have experienced significant advances of patients able to extend survival and/or progression free disease. Within the tumor microenvironment, a number of imm ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Nanosecond Laser and Ultrasound to Selectively Treat Eye Blood Vessels

    SBC: Photosonox LLC            Topic: NEI

    ABSTRACT / PROJECT SUMMARY Wet age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. Anti-VEGF therapy is currently the gold standard for wet AMD treatment. However, up to 50% of patients in the long term have a suboptimal response to anti-VEGF therapy. A better alternative method for treatment of AMD is urgently needed. We have recently inve ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NEI

    ABSTRACT Infection of the eye by Herpes Simplex Virus-1 (HSV-1) can result in Herpes Keratitis (HK), which is the leading cause of corneal blindness worldwide. Ocular herpes infections are often recurrent and culminate in progressive corneal scarring and loss of vision. The gold standard treatment is Acyclovir (ACV) that targets HSV-1 thymidine kinase (TK). Although ACV is highly effective against ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Next-generation precision medicine for targeting recombination-deficient cancers

    SBC: Recombination Therapeutics, LLC            Topic: O

    Precision medicine is a revolutionary therapeutic approach in which therapies are designed and selected based on genetic mutations present in certain cancers. For example, treating patients with BRCA-deficient cancers with a medicine that inhibits a particular DNA repair pathway can result in selective killing of these cancer cells. This approach is based upon the concept of synthetic lethality wh ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Pharmacological chaperones for the treatment of Open-Angle Glaucoma

    SBC: Viewpoint Therapeutics, Inc.            Topic: NEI

    Open-angle glaucoma is the second leading cause of blindness worldwide, affecting nearly 70 million individuals. Nonsynonymous mutations in the myocilin gene lead to the most common hereditary form of open-angle glaucoma and account for 3-4% of all cases. Disease-causing mutations, localized to its olfactomedin domain (mOLF), destabilize the myocilin protein, leading to its misfolding and accumula ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Reversal of Tau Pathology with MSUT2 siRNA Conjugates

    SBC: DTx Pharma, Inc.            Topic: NIA

    Project Summary Genetic and pathologic evidence in andapos;pureandapos; tauopathies such as Progressive Supranuclear Palsy (PSP), Corticobasilar Degeneration (CBD) and some cases of Fronto-temporal Dementia (FTD) directly implicate tau as causing neuronal cell death, while in Alzheimer’s Disease (AD) tau accumulation correlates with development and progression of cognitive impairment. Because of ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Hemoglobin-based antidotes for the treatment of carbon monoxide poisoning

    SBC: Globin Solutions, Inc.            Topic: NIEHS

    Project Summary/AbstractCarbon monoxide (CO) poisoning remains a major cause of death and disability, affecting 50,000 persons a year in the U.S. alone. Victims removed from fires or rescued after exposure to car or home generator exhaust only have two options: 100% oxygen or transfer via ambulance or medical evacuation helicopter to a specialized facility with emergency hyperbaric oxygen chamber. ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. A platform for engineering peptide ligase for building next generation peptide therapeutics.

    SBC: Scribe Biosciences, Inc.            Topic: 400

    PROJECT SUMMARY There is an increased interest in peptide medicines in pharmaceutical research and development (Randamp;D) because peptides are recognized as highly selective and efficacious, and at the same time relatively safe and well tolerated. Chemo-enzymatic peptide synthesis (CEPS) using peptide ligases features excellent purity and yield, thus becoming an attractive method to replace tradi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluation of a peptide that inhibitsthe activation of NOX2 and the generation of reactive oxygen species in protection against acute lung injury

    SBC: Peroxitech LLC            Topic: NHLBI

    SUMMARY: Acute lung injury (ALI) is a devastating complication of sepsis,viral and bacterial pneumonias, severe trauma with or without major blood loss, acid aspiration and other conditions that affect the lung either primarily or secondarily.This relatively common syndrome (~200,000 cases per yr in the US) currently has an overall mortality rate of ~40%. Lung inflammation associated with the prod ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government